A single-arm, open-label study evaluating the safety and efficacy of a single-dose administration of GS1191-0445 injection in Chinese patients with severe hemophilia A.
Latest Information Update: 30 Apr 2026
At a glance
- Drugs GS 1191 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Gritgen Therapeutics
Most Recent Events
- 23 Apr 2026 Actual primary completion date changed to 31 Dec 2024.
- 16 Feb 2026 New trial record.